These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9853192)

  • 1. Significance of reduction in heart rate in cardiovascular disease.
    Hjalmarson A
    Clin Cardiol; 1998 Dec; 21(12 Suppl 2):II3-7. PubMed ID: 9853192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does tight heart rate control improve beta-blocker efficacy? An updated analysis of the noncardiac surgical randomized trials.
    Beattie WS; Wijeysundera DN; Karkouti K; McCluskey S; Tait G
    Anesth Analg; 2008 Apr; 106(4):1039-48, table of contents. PubMed ID: 18349171
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials.
    Cucherat M
    Eur Heart J; 2007 Dec; 28(24):3012-9. PubMed ID: 17981830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Antianginal and antiadrenergic therapy in acute coronary syndrome].
    Raos V; Bergovec M
    Acta Med Croatica; 2004; 58(2):123-7. PubMed ID: 15208797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Heart rate: a cardiovascular risk factor that can no longer be ignored].
    Palatini P
    G Ital Cardiol (Rome); 2006 Feb; 7(2):119-28. PubMed ID: 16532723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interventions during and after acute myocardial infarction.
    Sleight P
    Postgrad Med J; 1983; 59 Suppl 3():80-8. PubMed ID: 6139802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resting heart rate in cardiovascular disease.
    Fox K; Borer JS; Camm AJ; Danchin N; Ferrari R; Lopez Sendon JL; Steg PG; Tardif JC; Tavazzi L; Tendera M;
    J Am Coll Cardiol; 2007 Aug; 50(9):823-30. PubMed ID: 17719466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-blocker underuse in secondary prevention of myocardial infarction.
    Everly MJ; Heaton PC; Cluxton RJ
    Ann Pharmacother; 2004 Feb; 38(2):286-93. PubMed ID: 14742768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated heart rate in cardiovascular diseases: a target for treatment?
    Palatini P
    Prog Cardiovasc Dis; 2009; 52(1):46-60. PubMed ID: 19615493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Calcium antagonists in cardiovascular disease. Clinical evidence from morbidity and mortality trials].
    Oparil S; Bakir SE
    Drugs; 2000; 59 Spec No 2():25-37. PubMed ID: 11002856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium antagonists in cardiovascular diseases].
    Thuillez C
    Arch Mal Coeur Vaiss; 1995 Sep; 88 Spec No 4():9-12. PubMed ID: 7503623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cellular and physiologic effects of beta blockers in heart failure.
    Sabbah HN
    Clin Cardiol; 1999 Oct; 22 Suppl 5():V16-20. PubMed ID: 10526699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose beta-blockers and tight heart rate control reduce myocardial ischemia and troponin T release in vascular surgery patients.
    Feringa HH; Bax JJ; Boersma E; Kertai MD; Meij SH; Galal W; Schouten O; Thomson IR; Klootwijk P; van Sambeek MR; Klein J; Poldermans D
    Circulation; 2006 Jul; 114(1 Suppl):I344-9. PubMed ID: 16820598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relevance of sympathetic activity in the pharmacological treatment of chronic stable angina.
    Singh BN
    Can J Cardiol; 1999 Mar; 15 Suppl A():15A-21A. PubMed ID: 10205252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM; Vitale C; Volterrani M
    Adv Ther; 2010 Apr; 27(4):202-10. PubMed ID: 20495895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E; Bonadei I; D'Aloia A; Del Magro F; Piovanelli B; Bontempi L; Curnis A; Dei Cas L
    Minerva Med; 2011 Oct; 102(5):373-9. PubMed ID: 22193347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Availability of new therapy increases interest in lowering heart rate to improve cardiovascular disease outcomes.
    Cardiovasc J S Afr; 2007; 18(1):63-4. PubMed ID: 17393008
    [No Abstract]   [Full Text] [Related]  

  • 18. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Can reduction in resting heart rate be beneficial for patients?].
    Soucek M
    Vnitr Lek; 2007 Apr; 53(4):401-3. PubMed ID: 17578174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of metoprolol and ivabradine on left ventricular remodelling and Ca2+ handling in the post-infarction rat heart.
    Maczewski M; Mackiewicz U
    Cardiovasc Res; 2008 Jul; 79(1):42-51. PubMed ID: 18310678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.